Clinical effect of Qingyang Huoxue No.2 Prescription on acute ischemic stroke associated pneumonia in the elderly with the syndrome of qi defi-ciency,phlegm-heat stasis,and obstruction
Objective To investigate the clinical effect of Qingyang Huoxue No.2 Prescription on acute ischemic stroke associated pneumonia(SAP)in the elderly with the syndrome of qi deficiency,phlegm-heat stasis,and obstruction.Methods Sixty-six elderly patients with acute ischemic SAP with the syndrome of qi deficiency,phlegm-heat stasis,and obstruction admitted to Chongqing Hospital of Traditional Chinese Medicine from February 2021 to December 2022 were selected and divided into observation group(33 cases)and control group(33 cases)by random number table method.The control group was given standardized treatment,and the observation group was given Qingyang Huoxue No.2 Prescription based on the control group.After ten days of treatment,the clinical effect of the two groups was compared.Chinese medicine syndrome score,National Institutes of Health stroke scale score(NIHSS),acute physiology and chronic health evaluation-Ⅱ(APACHEⅡ)score,clinical pulmonary infection score(CPIS),systemic inflammatory response syndrome(SIRS)score,and serum procalcitonin(PCT)levels were compared between the two groups before treatment and the fifth,tenth day of treatment.The incidence of adverse reactions in the two groups during treatment was analyzed.Results The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P＜0.05).Chinese medicine syndrome score,serum PCT level,NIHSS,APACHEⅡscore,SIRS,CPIS in two groups at the fifth,and tenth day of treatment were lower than those before treatment,and those at the tenth day of treatment were lower than those at five days after treatment,the differences were statistically significant(P＜0.05).Chinese medicine syndrome scores,APACHEⅡscore,SIRS in the observation group at the fifth and tenth day of treatment were lower than those in the control group at the same period,and NIHSS,CPIS,and serum PCT level in the observation group at the tenth day of treatment were lower than those in the control group at the same period,the differences were statistically significant(P＜0.05).No drug allergy,skin,drug-induced liver,and kidney damage or other adverse reactions occurred in the two groups during treatment.Conclusion Qingyang Huoxue No.2 Prescription can improve the Chinese medicine syndrome of elderly patients with acute ischemic SAP,improve the overall curative effect,and have good safety.
NETL
NSTL
万方数据
